Core Insights - The acquisition of Qinhuai Data's China operations by Dongyangguang Group and its partners for 28 billion yuan marks one of the largest computing power industry acquisitions in Asia in recent years, indicating a significant step towards enhancing industrial synergy and efficiency [1] - This acquisition allows Dongyangguang to leverage Qinhuai Data's expertise in data center construction, operation management, and computing power services, thereby strengthening its comprehensive capabilities in related service areas [1] - The collaboration is expected to create a more efficient, green, and sustainable computing power service capability, enhancing resource utilization efficiency through the integration of Dongyangguang's strengths in material technology, energy management, and liquid cooling with Qinhuai Data's operational scenarios [1] Industry Perspective - The successful completion of this acquisition reflects Dongyangguang Group's strategic execution in promoting industrial synergy and integrating quality resources [2] - As the integration of both businesses deepens, Dongyangguang is likely to establish a more competitive service system in related fields, providing strong support for high-quality corporate development [2]

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 2026-04 号 | | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | 广东东阳光科技控股股份有限公司 2025 年 9 月 10 日，广东东阳光科技控股股份有限公司（以下简称"公司"、 "上市公司"或"东阳光"）召开了第十二届董事会第十七次会议并审议通过了 《关于与关联方共同增资合资公司用于收购秦淮数据中国 100%股权暨关联交易 的议案》，同意公司与控股股东深圳市东阳光实业发展有限公司（以下简称"深 圳东阳光实业"）共同对宜昌东数一号投资有限责任公司（以下简称"东数一号"） 进行增资（以下简称"本次增资"）。同时，东数一号通过全资孙公司宜昌东数 三号投资有限责任公司（以下简称"东数三号"）收购秦淮数据中国区业务经营 主体（以下简称"秦淮数据中国"或"标的公司"）100%股权（以下简称"本 次收购"，与本次增资合称"本次交易"），并由东数三号与交易对方 Stack HK Limited、BCPE Stack ZJK Limited、WT Alpha Ltd、吴华鹏、 ...

格隆汇1月16日丨东阳光(600673.SH)公布，截至本公告披露日，公司已合计向东数一号出资34.5亿元， 履行完毕本次增资的出资义务。同时，东数三号已按照协议约定，完成向卖方支付合计280亿元的交易 价款（含代扣代缴税款）。截至本公告披露日，本次交易涉及的交易价款已全部支付完毕，公司及交易 各方已按照协议约定完成本次交易的交割工作。 ...

格隆汇1月16日丨东阳光(600673.SH)公布，截至本公告披露日，公司已合计向东数一号出资34.5亿元， 履行完毕本次增资的出资义务。同时，东数三号已按照协议约定，完成向卖方支付合计280亿元的交易 价款（含代扣代缴税款）。截至本公告披露日，本次交易涉及的交易价款已全部支付完毕，公司及交易 各方已按照协议约定完成本次交易的交割工作。 ...

东阳光公告，公司与控股股东深圳市东阳光实业发展有限公司共同对宜昌东数一号投资有限责任公司进 行增资，已合计向东数一号出资34.5亿元。同时，东数一号通过全资孙公司宜昌东数三号投资有限责任 公司完成向卖方支付合计280亿元的交易价款（含代扣代缴税款）。本次交易涉及的交易价款已全部支 付完毕，公司及交易各方已按照协议约定完成本次交易的交割工作。 ...

格隆汇1月16日｜东阳光(600673.SH)公告称，公司已合计向东数一号出资34.5亿元，履行完毕本次增资 的出资义务。同时，东数三号已完成向卖方支付合计280亿元的交易价款（含代扣代缴税款）。本次交 易涉及的交易价款已全部支付完毕，公司及交易各方已完成本次交易的交割工作。 ...

Group 1 - The company Dongyangguang Pharmaceutical has received approval from the National Medical Products Administration of China for its SGLT-2 inhibitor, Ologliptin capsules, which are intended for improving blood glucose control in adults with type 2 diabetes [1] - The approval is based on two Phase III clinical trials that demonstrated statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with improvements in fasting blood glucose and postprandial blood glucose [1] - The product also showed additional metabolic benefits, including weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood glucose, weight, and blood pressure [1] Group 2 - Diabetes is now the third most serious chronic non-communicable disease globally, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The company has a comprehensive product line in diabetes treatment, including five insulin products that have been approved and are consistent in effectiveness, safety, and quality with original formulations [2] - The new product approval will enhance the company's diabetes product portfolio, and the company plans to leverage its established production system and marketing network for rapid commercialization while exploring further clinical applications for diabetes complications [2]

Group 1 - The company Dongyangguang Pharmaceutical has received approval from the National Medical Products Administration of China for its innovative drug, Ologliptin capsules, which are designed to improve blood sugar control in adults with type 2 diabetes [1] - The approval is based on two Phase III clinical trials that demonstrated statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with improvements in fasting blood glucose and postprandial blood glucose [1] - The product also offers additional metabolic benefits such as weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood sugar, weight, and blood pressure [1] Group 2 - Diabetes has become the third most serious chronic non-communicable disease globally, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The company has a comprehensive product line in the diabetes treatment field, including five insulin products that have been approved and are consistent in efficacy, safety, and quality with original formulations [2] - The approval of the new product will enhance the company's diabetes product portfolio, and it plans to leverage its established production system and marketing network for rapid commercialization while exploring further clinical applications for diabetes complications [2]

Group 1 - Dongyangguang Pharmaceutical (06887.HK) announced that its self-developed SGLT-2 inhibitor, Oloklignet capsules (brand name: Dongzean, specifications: 20mg, 50mg), received approval from the National Medical Products Administration of China for marketing, aimed at improving blood glucose control in adult patients with type 2 diabetes, either as monotherapy or in combination with metformin [1] - The registration approval was based on two multicenter, randomized, double-blind, placebo-controlled Phase III clinical studies, which showed statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with significant improvements in fasting blood glucose and postprandial blood glucose [1] - The product also demonstrated additional metabolic benefits, including weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood glucose, weight, and blood pressure [1] Group 2 - Diabetes has become the third most serious chronic non-communicable disease globally, following cancer and cardiovascular diseases, with the International Diabetes Federation reporting a diabetes prevalence rate of 13.79% among adults (ages 20-79) in China, translating to approximately 148 million patients, the highest in the world [2] - Over 90% of these cases are type 2 diabetes, with a poor medication adherence rate and an effective blood glucose control rate of only 50.1% [2] - The company has a comprehensive product line in the diabetes treatment field, having developed five insulin products that have been approved for marketing, all of which are consistent in efficacy, safety, and quality with original formulations and have been included in the national drug centralized procurement [2] - The approval of the new product will further enrich the company's diabetes product line, leveraging its established production system and marketing network for rapid commercialization, while also exploring clinical applications in diabetes complications to expand the range of indications [2]

Core Viewpoint - Dongyangguang Pharmaceutical's innovative drug Ologliptin capsules have been approved by the National Medical Products Administration for the treatment of adult type 2 diabetes, providing a "China innovation" therapeutic solution for patients [1] Group 1: Product Approval and Market Impact - Ologliptin is indicated for use as a monotherapy or in combination with metformin to improve blood glucose control in adult patients with type 2 diabetes [1] - The approval of Ologliptin represents a significant advancement in diabetes treatment options available in China, emphasizing the importance of domestic innovation in the pharmaceutical industry [1] Group 2: Clinical Data and Competitive Advantage - Clinical data indicates that Ologliptin shows superior reductions in fasting blood glucose and postprandial blood glucose levels compared to existing treatments [1] - The ability of Ologliptin to stabilize fasting blood glucose levels, which are often early indicators of diabetes complications, suggests a strong competitive edge in precise glucose control [1] - The drug offers comprehensive coverage of blood glucose levels throughout the day, addressing both fasting and postprandial periods effectively [1]